Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTOG-9413: Radiation and Androgen Suppression in Prostate Cancer
NCT00769548Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Apr 1995
- Primary completion
- Apr 2001
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 3 trial of goserelin, flutamide in prostate cancer (PCa), sponsored by NRG Oncology. Started Apr 1995; status: completed.
02
Drugs
goserelinflutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00769548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769548.